A Single-Centre Experience of First-Line Romiplostim and Immunosuppressive Therapy in Patients With Aplastic Anemia

Background Romiplostim, a thrombopoietin (TPO) receptor antagonist, promotes tri-lineage hematopoiesis in patients with acquired aplastic anemia (AA). However, its efficacy as a first-line treatment in combination with an immunosuppressant, i.e., anti-thymocyte globulin (ATG) and cyclosporine (CSA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhingra, Gaurav, Rajoreya, Ashok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190113/
https://www.ncbi.nlm.nih.gov/pubmed/37206485
http://dx.doi.org/10.7759/cureus.37682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190113/
https://www.ncbi.nlm.nih.gov/pubmed/37206485
http://dx.doi.org/10.7759/cureus.37682

Ejemplares similares